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Introduction {#sec005}
============

Henoch-Schönlein purpura (HSP) is the most common small vessel vasculitis in childhood, with an annual incidence of 10--20 per 100,000. More than 90% of patients are younger than 10 years old \[[@pone.0167346.ref001]\]. The clinical features of HSP have been well described and are predominantly non-thrombocytopenic purpura, arthritis, abdominal pain, gastrointestinal bleeding, and glomerulonephritis. Numerous investigations suggest that HSP is not a self-limited disease as previously thought and may eventually develop into chronic kidney disease in childhood \[[@pone.0167346.ref002]--[@pone.0167346.ref003]\]. Long-term prognosis depends mainly on the severity of renal involvement, which may manifest as persistent hematuria, proteinuria, nephritic or nephrotic syndrome, or even renal failure \[[@pone.0167346.ref004]\]. To prevent or delay end-stage renal disease, identification of early-stage nephritis is crucial.

The risk factors associated with renal involvement in HSP are not well known although epidemiologic and clinical features and some abnormal laboratory findings have been suggested to have a predictive role \[[@pone.0167346.ref005]\]. In this meta-analysis, we assessed the quality of available evidence regarding risk factors that may predict renal involvement in childhood HSP, and present a summary of our results.

Methods {#sec006}
=======

Literature search strategy {#sec007}
--------------------------

The databases PubMed, Embase, and Web of Science were searched for papers published from January 2000 to September 2016, using basic search terms from combined text and Medical Subject Heading (MeSH) terms, including a MeSH search using 'Purpura, Henoch-Schönlein' and a keyword search using the word 'Henoch-Schönlein purpura', and terms related to risk factors (including a MeSH search using 'Risk Factors', and a keyword search using the words 'risk factors'). This search strategy was modified to fit each database. References from published review articles were reviewed to identify additional relevant studies ([S1 Text](#pone.0167346.s003){ref-type="supplementary-material"}). Cohort studies or case-control studies that evaluated the risk factors for developing HSP nephritis (HSPN) were included. Titles and abstracts of articles found were screened, and articles of interest were also selected for evaluation of the full article.

Study selection criteria {#sec008}
------------------------

Patients were diagnosed with HSP at \< 18 years of age, with consideration for the criteria of the American College of Rheumatology (ACR) \[[@pone.0167346.ref006]\] and definitions of the European League against Rheumatism (EULAR) \[[@pone.0167346.ref007]\], in which HSPN is defined as the presence of hematuria or proteinuria at two different times within 6 months of HSP onset. Renal involvement was defined as the presence of proteinuria, hematuria, or blood cell casts. The studies in our meta-analysis must include detailed information after the onset of HSP and the length of follow-up time should be increased at least up to 6 months. Thrombocytopenia and systemic lupus erythematosus at the onset were excluded.

Data collection and data extraction {#sec009}
-----------------------------------

Studies were selected by 2 independent reviewers according to the predetermined inclusion criteria, and disagreements were resolved by a third reviewer. Case reports, genetic association studies, review articles, comments, meeting abstracts, and editorial comments were excluded. The extracted data included the studies' characteristics (publication year), design features, participants (e.g., setting, ethnicity, case number, age, male/female ratio, positive cases of HSP and HSPN, factors (e.g., the laboratory predictors), and diagnostic criteria.

Bias and quality assessments of the included studies {#sec010}
----------------------------------------------------

The recommended checklist of the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) initiative was used to assess the risk of bias of the included studies \[[@pone.0167346.ref008]\]. A quality assessment of the studies was performed using Newcastle-Ottawa scale, NOS (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>), under three main categories: a selection of study; comparability of groups; and determination of outcomes \[[@pone.0167346.ref009]\].

Statistical analysis {#sec011}
--------------------

We estimated the odds ratio (OR) with 95% confidence interval (CI) for dichotomous outcomes. A random-effects model was used regardless of heterogeneity. Heterogeneity among trials was tested using the I^2^ test and considered significant at I^2^ \> 50% or *P*- value \< 0.1. The random effects model was used for the meta-analysis if there was significant heterogeneity. Subgroup analyses were conducted regarding interval levels in the risk factors (e.g., gender), quality of evidence, and diagnosed criteria. Sensitivity analyses were performed to evaluate the effect of each study on the pooled ORs. The presence of publication bias was also evaluated using the Begg's and Egger's test \[[@pone.0167346.ref010],[@pone.0167346.ref011]\]. All statistical analyses were performed using Stata 12.0 software (Stata Corp, College Station, TX, (USA) \[[@pone.0167346.ref012]\].

Results {#sec012}
=======

Study selection and characteristics {#sec013}
-----------------------------------

Initially, 386 potentially relevant studies were considered ([Fig 1](#pone.0167346.g001){ref-type="fig"}), but only 13 studies satisfied the inclusion and exclusion criteria and were included in this meta-analysis ([Table 1](#pone.0167346.t001){ref-type="table"}). These studies were published between 2000 and 2016, and all of them are case-control studies. Two were conducted in Turkey, four in China, and one each in Japan, Korea, Spain, Brazil, Finland, Iran, and Thailand. Studies were performed in 2 major ethnic populations; 8 studies were conducted in Asia (6 East Asian), while 5 studies were conducted with Caucasians. Five studies used the criteria of the EULAR, and 8 used the criteria of the ACR. The 13 studies comprised 2398 children with HSP; 974 of these children had renal involvement.

![Flowchart of selection process for eligible studies (PRISMA 2009 flow diagram).](pone.0167346.g001){#pone.0167346.g001}

10.1371/journal.pone.0167346.t001

###### Basic characteristics of included studies[^a^](#t001fn001){ref-type="table-fn"}

![](pone.0167346.t001){#pone.0167346.t001g}

                                              Year   Setting    Ethnicity   HSPN/HSP   Age HSPN/HSP, y       Risk factors [^b^](#t001fn002){ref-type="table-fn"}   Criterion
  ------------------------------------------- ------ ---------- ----------- ---------- --------------------- ----------------------------------------------------- -----------
  Shin \[[@pone.0167346.ref015]\]             2006   Korea      Asian       78/128     8.2 ± 3.1/6.7 ± 2.6   1 2 3 4 5 6 7 8 9 10 11 12 14 17                      ACR
  Jauhola \[[@pone.0167346.ref013]\]          2015   Finland    Caucasian   102/121    8.2 ± 3.8/6.2 ± 3.0   1 2 4 7 8 13 14 15 16                                 ACR
  Zhao \[[@pone.0167346.ref019]\]             2015   China      Asian       45/96      7.8 ± 2.6             1 2 3 4 7 10 11 12 13 17                              EULAR
  Elmas \[[@pone.0167346.ref016]\]            2014   Turkey     Caucasian   28/79      8.7 ± 4.1/7.1 ± 3.0   1 2 7 9 10 11 13 14 16                                EULAR
  Mao \[[@pone.0167346.ref020]\]              2014   China      Asian       267/268    7.5 ± 2.7/6.4 ± 2.5   1 2 7 9 10 11 14 16                                   EULAR
  Anil \[[@pone.0167346.ref017]\]             2011   Turkey     Caucasian   192/238    7.9 ± 2.8/7.5 ± 2.8   1 2 6 8 9 11 13                                       ACR
  Zhu \[[@pone.0167346.ref021]\]              2014   China      Asian       80/38      10.41 ± 2.70          1 2 7 8 9 14 15 17                                    ACR
  Mariac \[[@pone.0167346.ref014]\]           2001   Spain      Caucasian   8/61       6.9 ± 2.2/6.1 ± 3.3   1 2 5 6 7 8 9 13 14                                   ACR
  Kawasaki \[[@pone.0167346.ref018]\]         2003   Japan      Asian       15/69      9.6 ± 3.7/8.7 ± 3.1   1 4 7 14 16 17                                        ACR
  Limpongsanurak \[[@pone.0167346.ref022]\]   2011   Thailand   Asian       11/156     6.9 ± 2.6             5 7 12                                                ACR
  Luiz \[[@pone.0167346.ref023]\]             2007   Brazil     Caucasian   70/72      ------                1 2 3 4 5 6 7 14                                      ACR
  Wang \[[@pone.0167346.ref024]\]             2016   China      Asian       37/34      8.6 ± 2.1             1 2 7 11 14                                           EULAR
  Nickavar \[[@pone.0167346.ref025]\]         2012   Iran       Caucasian   41/64      7.3 ± 2.6/5.3 ± 2.7   2 5 7                                                 EULAR

^a^ All studies were case-control studies

^b^ Risk factor key: 1, age; 2, gender; 3, persistent purpura; 4, abdominal pain; 5, severe bowel angina; 6, gastrointestinal bleeding; 7, arthritis/arthralgia; 8, relapse; 9, leukocytosis; 10, thrombocytosis; 11, CRP; 12, ASO; 13, ESR; 14, IgA; 15, IgE; 16, IgG; 17, C3.

Quality of evidence {#sec014}
-------------------

NOS scale for case-control studies was applied to assess the quality of the evidence. Six studies were judged to be of high relative quality \[[@pone.0167346.ref013]--[@pone.0167346.ref018]\] and 7 were of medium quality \[[@pone.0167346.ref019]--[@pone.0167346.ref025]\]. In the selected studies, the controls were not community-based except for Jauhola \[[@pone.0167346.ref013]\] and Mariac \[[@pone.0167346.ref014]\]. An additional unclear confounder was not controlled within comparability categories, which may be a possible source of bias. In addition, all of the 7 medium-quality studies may contain bias due to a relatively short-term follow-up. ([Table 2](#pone.0167346.t002){ref-type="table"})

10.1371/journal.pone.0167346.t002

###### Newcastle-Ottawa quality assessment scale (case-control) for studies included in this meta-analysis

![](pone.0167346.t002){#pone.0167346.t002g}

                                                                                                                                                                                                                                                                                                                                                        1       2       3       4       5       6       7       8       9       10      11      12      13
  ------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Was the case definition adequate     **a.** Yes, with independent validation[\*](#t002fn001){ref-type="table-fn"}; **b.** yes, e.g., record linkage or based on self-reports; **c.** no description                                                                                                                                                   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**
  Representativeness of the case       **a.** Consecutive or obviously representative series of cases[\*](#t002fn001){ref-type="table-fn"}; **b.** potential for selection biases or not stated                                                                                                                                                         **●**   **●**                           **●**           **●**   **●**                           
  Selection of controls                **a.** Community controls[\*](#t002fn001){ref-type="table-fn"}; **b.** hospital controls; **c.** no description                                                                                                                                                                                                          **●**                                           **●**                                   
  Definition of controls               **a.** No history of disease (endpoint[\*](#t002fn001){ref-type="table-fn"}; **b.** no description of source                                                                                                                                                                                                     **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**
  Comparability                        **a.** Study controls for\_ \_ \_ \_(selecting the most important factor)[\*](#t002fn001){ref-type="table-fn"}; **b.** study controls for any additional factor[\*](#t002fn001){ref-type="table-fn"}                                                                                                             **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**
  Ascertainment of exposure            **a.** Secure record (e.g., surgical records)[\*](#t002fn001){ref-type="table-fn"}; **b.** structured interview where blind to case/control status interview not blinded to case/control status[\*](#t002fn001){ref-type="table-fn"}; **d.** written self-report or medical record only; **e.** no description   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**
  Ascertainment for cases & controls   **a.** Yes[\*](#t002fn001){ref-type="table-fn"} **b.** No                                                                                                                                                                                                                                                        **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**
  Non-response rate                    **a.** Same rate for both groups[\*](#t002fn001){ref-type="table-fn"}; **b.** non-respondents described; **c.** rate different and no designation                                                                                                                                                                **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**   **●**
  Score                                                                                                                                                                                                                                                                                                                                                 7       8       6       7       6       7       6       8       7       6       6       6       6

\*Scored points

The control group of each study was selected from the same population as the case group and was confirmed without kidney damage after the follow-up period. Controls were selected independently by exposure status and without special clinical features. Both groups completed the follow-up time and had similar rates of non-response. To ensure an efficient and valid study, selection and restrict enrollment for patients was conducted in each study. In addition, a stratified analysis (e.g., gender, age, clinical manifestation) and logistic regression for multivariate analysis for confounding factors (except for Limpongsanurak \[[@pone.0167346.ref022]\] and Nickavar \[[@pone.0167346.ref025]\]) were conducted in all selected studies. All the analyzed risk factors were shown to be directly linked with renal damage.

Results of meta-analysis {#sec015}
------------------------

We observed a consistent significant association between 12 risk factors and renal involvement in childhood HSP: gender, age, abdominal pain, gastrointestinal bleeding, severe bowel angina, persistent or relapse purpura, WBC \> 15 × 10^9^/L, platelet count \> 500 × 10^9^/L, elevated ASO, and decreased complement component 3 (C3; [Table 3](#pone.0167346.t003){ref-type="table"} and Figs [2](#pone.0167346.g002){ref-type="fig"}--[5](#pone.0167346.g005){ref-type="fig"}). In addition, there was no association between girls with HSP and HSPN (OR 1.15; 95% CI \[0.77--1.71\]) where *P* = 0.12. Arthritis/arthralgia may be a risk factor according to the criteria of the ACR in our analysis (1.41, 1.01--1.96, [Fig 6](#pone.0167346.g006){ref-type="fig"}).

![Forest plots of OR/WMD estimates for the following risk factors: (A) age; (B) gender: (C) older age](pone.0167346.g002){#pone.0167346.g002}

![Forest plots of OR estimates for the following risk factors: abdominal pain; gastrointestinal bleeding; severe bowel angina; arthritis or arthralgia; blood pressure; orchitis; persistent purpura; relapse](pone.0167346.g003){#pone.0167346.g003}

![Forest plots of OR estimates for the following risk factors: ASO; CRP; ESR; leukocytosis; thrombocytosis](pone.0167346.g004){#pone.0167346.g004}

![Forest plots of OR estimates for the following risk factors: IgA; IgE; IgG; C3](pone.0167346.g005){#pone.0167346.g005}

![Result of sensitivity analysis and subgroup analysis on arthritis/ arthralgia.](pone.0167346.g006){#pone.0167346.g006}

10.1371/journal.pone.0167346.t003

###### Results of meta-analysis by system

![](pone.0167346.t003){#pone.0167346.t003g}

                         Possible risk factors       Inconclusive     Results
  ---------------------- --------------------------- ---------------- ------------------------------------------------------
                         Age                                          Older age WMD = 0.90,95% CI (0.61--1.19), P = 0.00
                                                                      \>10 year-old = 3.13,95% CI (1.39--7.07), *P* = 0.06
                         Boy                                          OR = 1.36,95% CI (1.07--1.74), *P* = 0.02
                                                     Girl             OR = 1.15,95% CI (0.77--1.71), *P* = 0.15
  Digestive tract        Abdominal pain                               OR = 1.94,95% CI (1.24--3.04), *P* = 0.04
                         Gastrointestinal bleeding                    OR = 1.86,95% CI (1.30--2.65), *P* = 0.70
                         Severe bowel angina                          OR = 3.38,95% CI (1.17--9.80), *P* = 0.02
  Skeletal               Arthritis/arthralgia                         OR = 1.41,95% CI (1.01--1.96), *P* = 0.60
  Dermal                 Persistent purpura                           OR = 4.02,95% CI (1.22--13.25), *P* = 0.02
                         Relapse                                      OR = 4.70,95% CI (2.42--9.14), *P* = 0.00
                                                     Blood pressure   OR = 1.10,95% CI (0.63--1.92), *P* = 0.42
                                                     Orchitis         OR = 0.94,95% CI (0.30--2.94), *P* = 0.33
  Routine blood test     WBC \> 15 × 10^9^/L                          OR = 2.42,95% CI (1.39--4.22), *P* = 0.00
                         PLT \> 500 × 10^9^/L                         OR = 2.98,95% CI (1.22--7.25), *P* = 0.02
                         Positive ASO                                 OR = 2.17,95% CI (1.29--3.64), *P* = 0.00
                                                     Elevated ESR     OR = 0.90,95% CI (0.65--1.23), *P* = 0.33
                                                     Elevated CRP     OR = 1.33,95% CI (0.77--2.28), *P* = 0.06
  Immunologic function                               Elevated IgA     OR = 1.24,95% CI (0.65--2.37), *P* = 0.02
                                                     Elevated IgE     OR = 1.06,95% CI (0.45--2.49), *P* = 0.19
                                                     Elevated IgG     OR = 0.65,95% CI (0.22--1.90), *P* = 0.41
                         Decreased C3                                 OR = 3.13,95% CI (1.62--6.05), *P* = 0.91

Subgroup and sensitivity analysis {#sec016}
---------------------------------

Except for arthritis/arthralgia, the subgroup analysis showed no evidence of heterogeneity between ACR and EULAR ([Fig 6](#pone.0167346.g006){ref-type="fig"}). The sensitivity analysis showed that no individual study significantly altered the results, except for the medium-quality study of Zhao et al. \[[@pone.0167346.ref019]\], which was the main origin of heterogeneity in abdominal pain ([Fig 7](#pone.0167346.g007){ref-type="fig"}). After the deletion of the study, the heterogeneity vanished ([Fig 8](#pone.0167346.g008){ref-type="fig"}). A further analysis of studies of different quality revealed that although studies of higher quality may have a more positive effect than medium-quality studies, both had similar results ([S2 Appendix](#pone.0167346.s002){ref-type="supplementary-material"}). Therefore, the data of each study in the meta-analysis was relatively stable and credible.

![Result of sensitivity analysis on abdominal pain.](pone.0167346.g007){#pone.0167346.g007}

![Forest plots of OR estimates for abdominal pain after the deletion of an unstable study.](pone.0167346.g008){#pone.0167346.g008}

Publication bias {#sec017}
----------------

Assessment of publication bias using Egger's and Begg's tests showed that there was no potential publication bias among the included trials (e.g., gender; Egger's test *P* = 0.46, Begg's test, *P* = 0.78; [Fig 9](#pone.0167346.g009){ref-type="fig"}).

![Assessment of Publication bias using (A) Egger's and (B) Begg's test.](pone.0167346.g009){#pone.0167346.g009}

Discussion {#sec018}
==========

The possible risk factors of renal involvement in childhood Henoch-Schönlein purpura have been reported during past 15 years. Future studies should include a better definition of patients at risk, and then treatment and clinical trials should be adapted to patients' risk profiles \[[@pone.0167346.ref026]\]. The present study attempted to determine comprehensively the effect of a multitude of possible risk factors of renal involvement in childhood HSP. The risk factors included demographic features; (age, gender), clinical features; (gastrointestinal tract, skeletal system, skin, testicles, and blood pressure) and some abnormal laboratory findings (such as elevated ASO, elevated ESR, elevated CRP, elevated IgA/IgE/IgG and decreased C3).

A previous meta-analysis was published by Mao et al. \[[@pone.0167346.ref027]\], which suggested that older age; elevated blood pressure, C3, hemoglobin, and urea nitrogen; and decreased albumin were risk factors for renal damage in HSP patients. In detail, the analysis included 8 studies (12 possible risk factors) and comprised 1222 patients, most of which were experimental studies without follow-up and focused only on laboratory findings in HSP patients. To acquire adequate and reliable clinical literature, our meta-analysis adopted a strict search strategy and included 13 studies (additional 1176 patients and 20 possible risk factors) that concern not only abnormal laboratory findings, but also focus on other vital risk factors (e.g., epidemiological features and clinical manifestations) in children with HSP. Meanwhile, we further assessed heterogeneity by performing subgroup or sensitivity analyses of stratified risk factors (e.g., gender), quality of evidence, and diagnostic criteria of HSP which have a great bearing on the interpretation of the results. In addition, publication bias and potential confounding factors among the included trials were well analyzed in our meta-analysis.

The criteria of the ACR and EULAR were implemented to define HSP. Some studies have adopted the former, while others have utilized the European; Except for arthritis/ arthralgia sensitivity analyses have shown no evidence of heterogeneity observed between both. In fact, all patients with HSP complained of purpura without thrombocytopenia \[[@pone.0167346.ref028]\]. But while palpable purpura was found in 100% of the cases according to the ACR criteria, the EULAR criteria base a diagnosis of HSP on other symptoms \[[@pone.0167346.ref029]\].

The majority of patients were diagnosed between the ages of 2 and 10 years~.~ Sano et al. \[[@pone.0167346.ref030]\] concluded that age older than 4 years was an independent risk factor for renal involvement, while according to Jauhola et al. \[[@pone.0167346.ref013]\] age over 8 years at onset was a risk factor for developing nephritis. Our present meta-analysis showed that older children were at higher risk of renal involvement than younger children. Furthermore, the subgroup analysis revealed that children over 10 years old were more likely to suffer HSPN. Therefore, careful attention should be paid especially to children older than 10 years at onset ([Table 3](#pone.0167346.t003){ref-type="table"} and [Fig 2](#pone.0167346.g002){ref-type="fig"}).

Our meta-analysis based on 10 studies showed that boys are at higher risk for renal involvement than girls. This result is similar to a previous epidemiological survey based on 1.1 million children younger than 17 years in West Midland which reported a boy-to-girl ratio of 1.2:1.0 \[[@pone.0167346.ref031]\].Male predominance has also been reported in other studies \[[@pone.0167346.ref016], [@pone.0167346.ref032], [@pone.0167346.ref033]\]. Male hormones may have a pathogenic role in the course of HSP \[[@pone.0167346.ref034]\], but other studies reported that HSPN was more common in girls \[[@pone.0167346.ref014], [@pone.0167346.ref023]\] ([Table 3](#pone.0167346.t003){ref-type="table"} and [Fig 2](#pone.0167346.g002){ref-type="fig"}).

Digestive tract symptoms (abdominal pain, gastrointestinal bleeding, and severe bowel angina) and skeletal system symptoms (arthritis/arthralgia) are the predominant manifestations in HSP. The meta-analysis based on 4 studies showed that gastrointestinal bleeding also increased the risk of renal involvement. Even so, few published articles have recognized gastrointestinal bleeding as a risk factor in HSP, and more cohort studies are necessary to identify whether gastrointestinal bleeding is an independent risk factor of HSPN([Table 3](#pone.0167346.t003){ref-type="table"} and [Fig 3](#pone.0167346.g003){ref-type="fig"}).

Our review showed that digestive tract symptoms (abdominal pain, gastrointestinal bleeding, and severe bowel angina) were strongly related to renal involvement. In a retrospective study of 141 patients with HSP, Zhao et al. \[[@pone.0167346.ref019]\] showed that abdominal pain was not related to HSPN. However, 45% of the patients were complicated with obesity and 29.8% of them had a long disease course. This was a distinctly different epidemiological feature from other studies, and the possibility of admission bias could explain the heterogeneity ([Fig 7](#pone.0167346.g007){ref-type="fig"}). Abdominal pain and severe bowel angina are both unpleasant when patients suffer gastrointestinal involvement in HSP. Our analysis suggested that the two levels of gastrointestinal reactions are essentially equivalent for predicting renal injury in HSP. The mechanism probably is due to early systemic corticosteroid administration for severe abdominal pain, which did not prevent severe renal involvement \[[@pone.0167346.ref035]\]. As gastrointestinal symptoms are easily missed in clinical practice, more attention should be paid to these patients ([Table 3](#pone.0167346.t003){ref-type="table"} and [Fig 3](#pone.0167346.g003){ref-type="fig"}).

The sensitivity analysis showed a completely different result regarding arthritis/arthralgia between the criteria of the ACR and EULAR and the difference between two criteria may help to explain. For skeletal system symptoms (arthritis/arthralgia), a relatively independent type of HSP according to the criteria of the EULAR, patients with arthritis/arthralgia onset were assigned equally to the HSP or HSPN group. This distribution to compare these groups would not be possible if the criteria of the ACR were adopted ([Table 3](#pone.0167346.t003){ref-type="table"} and [Fig 3](#pone.0167346.g003){ref-type="fig"}).

Most identified studies showed an important association between abnormal skin manifestations (persistent purpura or relapse) and HSPN \[[@pone.0167346.ref036]\]. According to our meta-analysis, the risk of renal damage in HSP children with persistent purpura is 1.22--13.25-fold that of patients without persistent purpura, and the incidence of purpura relapse with renal involvement is 2.7-11-fold that of those who had no relapse. The study of Rigante et al. \[[@pone.0167346.ref037]\] showed that only persistent purpura for more than one month was a risk of renal involvement in HSPN. The mechanism probably is due to persistent small vascular inflammation and immune complex deposition, which triggers a series of inflammatory reactions that may damage kidney tissues ([Table 3](#pone.0167346.t003){ref-type="table"} and [Fig 3](#pone.0167346.g003){ref-type="fig"}).

Our analysis showed that WBC \>15 × 10^9^/L and platelet count \>500 × 10^9^/L were highly correlated with renal involvement in HSP, and a WBC of 10 × 10^9^/L to 15 × 10^9^/L has no statistical link to renal involvement. The mechanism may be a tissue injury induced by inflammatory agents secreted by neutrophils triggered by an inflammation-induced factor \[[@pone.0167346.ref037]\]. Anti-neutrophil cytoplasmic antibody was found to predict renal damage induced by HSP \[[@pone.0167346.ref038]\]. Thrombocytosis may be an early and useful indicator, and early studies have suggested that reducing the platelet count may be an effective method to avoid renal involvement \[[@pone.0167346.ref039], [@pone.0167346.ref040]\]. However, a systematic review and meta-analysis of 13 randomized controlled trials performed by Hahn et al. \[[@pone.0167346.ref041]\] revealed that there is no benefit in giving antiplatelet agents, such as dipyridamole and aspirin, to prevent kidney disease. Heparin may be effective but it is potentially dangerous and should be taken cautiously. Additionally, there are no evidence that prednisone is of benefit in preventing renal damage in HSP according to Hahn et al. \[[@pone.0167346.ref041]\] and Chartapisak et al. \[[@pone.0167346.ref042]\] ([Table 3](#pone.0167346.t003){ref-type="table"} and [Fig 4](#pone.0167346.g004){ref-type="fig"}).

ASO is an antibody specific to streptolysin, which indicates streptococcal infections. Most patients also had a history of upper respiratory tract infection \[[@pone.0167346.ref043]\] and a large proportion was infected with streptococci. Our analysis suggested that upper respiratory tract infection, especially streptococcal infection related to high ASO, precedes HSPN \[[@pone.0167346.ref044]\]. So far, the mechanism underlying an association between elevated upper respiratory tract infection with streptococcus and kidney damage in HSP is unknown. According to the analysis, elevated ESR and CRP are not related to HSPN ([Table 3](#pone.0167346.t003){ref-type="table"} and [Fig 4](#pone.0167346.g004){ref-type="fig"}).

From the reviewed literature, some patients with HSPN had low C3 (10%-20%), elevated IgA (20%-50%), or both \[[@pone.0167346.ref031]\]. Our analysis also revealed that low C3 is an independent risk factor in HSP, which is a feature of post-streptococcal glomerulonephritis. Fretzayas et al. \[[@pone.0167346.ref045]\] reported elevated IgA in 73% of all patients with HSP and in 95% of patients with HSPN, but latter studies did not confirm elevated IgA as a risk factor associated with HSPN. In our present analysis, elevated IgG and IgE may have no connection with HSPN. There were only two papers that reported a link between serum IgG and IgE and HSPN, but the data for our analysis was not sufficient to calculate the OR and obtain a reliable result ([Table 3](#pone.0167346.t003){ref-type="table"} and [Fig 5](#pone.0167346.g005){ref-type="fig"}).

Although some studies have claimed that high blood pressure and orchitis could be risk factors in HSP children, our meta-analysis showed that blood pressure and orchitis did not predict the occurrence of renal involvement ([Table 3](#pone.0167346.t003){ref-type="table"} and [Fig 3](#pone.0167346.g003){ref-type="fig"}).

In the meta-analysis, neither renal failure nor end stage renal disease were detected or described in the selected studies. HSP is more common among children than adults, but there are more end-stage renal disease events in adults \[[@pone.0167346.ref046]\]. However, management of HSP is difficult for pediatricians because of insufficient clinical data in adult stage. Previous studies reported that severity and persistence of proteinuria were predictive of eventual renal failure \[[@pone.0167346.ref047],[@pone.0167346.ref048]\] while Butani \[[@pone.0167346.ref049]\] and Sanders and [Wyatt](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wyatt%2520RJ%255BAuthor%255D&cauthor=true&cauthor_uid=18332712) \[[@pone.0167346.ref050]\]suggested that there are no clinical features or prognostic markers to reliably identify children at highest risk for disease progression. Limited numbers of patients and appropriate studies at presentation increase the difficulty in performing a meta-analysis of a link between HSPN and end stage renal disease. Therefore, a long-term follow-up should be conducted for children with HSPN to determine prognosis when there is renal involvement.

Early identification of the risk factors of renal involvement in HSP has important implications for intervention and management. A sensitive scoring system based on these risk factors at onset to predict HSPN may become a focus of research. For children with gastrointestinal tract symptoms at onset, early gastrointestinal endoscopy is a good tool for assisting diagnosis of HSP \[[@pone.0167346.ref051]\]. Children with more than one risk factor require more intervention than those who are without those risk factors. The effectiveness of relevant preventive actions has been confirmed: A clinical trial reported that leukocytapheresis could not only ameliorate gastrointestinal symptoms, but also prevent HSPN, persistent purpura, and relapse in HSP. For persistent purpura and relapse, cyproheptadine could help prevent or at least decrease the occurrence of HSPN in children \[[@pone.0167346.ref052]\].

Some shortcomings of the present meta-analysis should be considered. Firstly, our analysis was based only on case-control studies, and the above risk factors cannot be relied on as causal factors of renal involvement in HSP. The risk factors of renal injury in HSP remain unclear. Case reports that point to new risk factors are increasing every year, and these may be a source of confounding factors in the included studies. Secondly, measurements and missing data were not described in detail in most of the included studies, which may indicate a possible bias. Thirdly, grey literature was not considered, and only 2 major ethnic populations was included, which may result in reporting and ethnicity selection bias. Fourthly, although there is no statistical or clinical heterogeneity across the case-control studies, potential bias still exists because of the 2 HSP diagnostic systems. For atypical HSP children, we should take a cautious attitude towards the above risk factors. Finally, for several risk factors (e.g., age,leukocytosis, thrombocytosis, and elevated ASO), relevant literature is limited and verification from clinical data is required.

Conclusions {#sec019}
===========

In conclusion, our study highlights the following as factors associated with renal involvement in pediatric HSP: male gender, age \> 10 years, severe gastrointestinal symptoms (including abdominal pain, gastrointestinal bleeding, and severe bowel angina), arthritis/arthralgia, persistent purpura or relapse, WBC \> 15 × 10^9^/L, platelets \> 500 × 10^9^/L, elevated ASO, and decreased C3. More attention should be paid to those children who have one or more of the above risk factors, and a sensitive scoring system based on these risk factors at onset may help predict renal injury in HSP patients. Relevant clinical intervention may exert positive effects on the prevention of kidney disease in the early stage of HSP. Well-designed and conventionally reported studies with a considerable number of children with HSP are necessary to determine the possible link between these 13 risk factors and HSPN.
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ACR

:   American College of Rheumatology

ASO

:   antistreptolysin O

C3

:   complement component 3

CRP

:   C-reactive protein

ESR

:   erythrocyte sedimentation rate

EULAR

:   European League Against Rheumatism

HSP

:   Henoch-Schönlein purpura

HSPN

:   Henoch-Schönlein purpura nephritis

OR

:   odds ratio

WBC

:   white blood cell

WMD

:   weighted mean difference
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